Rapport Therapeutics (RAPP): Director Silva Paul M bought $99,636 worth of shares (3,680 units at $27.08) (SEC Form 4)

Historical context for RAPP

Across the 24 sessions after earlier RAPP headlines, the stock closed higher 17 times and lower 7 times, with a median move of 2.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

Earlier insider filings at RAPP

• Oct 22, 2026Director Young Wendy B. bought $99,992 worth of shares (3,789 units at $26.39) (SEC Form 4)
• Oct 22, 2026Director Paul Steven M bought $974,278 worth of shares (35,714 units at $27.28) (SEC Form 4)
• Oct 22, 2026Director Maraganore John bought $248,891 worth of shares (9,411 units at $26.45) (SEC Form 4)
• Oct 21, 2026Chief Financial Officer Ignelzi Troy A. bought $143,550 worth of shares (5,500 units at $26.10) (SEC Form 4)
• Oct 8, 2026Chief Executive Officer Ceesay Abraham sold $143,273 worth of shares (4,522 units at $31.68) as part of a pre-agreed trading plan (SEC Form 4)